Tumor regression mediated by oncogene withdrawal or erlotinib stimulates infiltration of inflammatory immune cells in EGFR mutant lung tumors

BACKGROUND: Epidermal Growth Factor Receptor (EGFR) tyrosine kinase inhibitors (TKIs) like erlotinib are effective for treating patients with EGFR mutant lung cancer; however, drug resistance inevitably emerges. Approaches to combine immunotherapies and targeted therapies to overcome or delay drug r...

Descripción completa

Detalles Bibliográficos
Autores principales: Ayeni, Deborah, Miller, Braden, Kuhlmann, Alexandra, Ho, Ping-Chih, Robles-Oteiza, Camila, Gaefele, Mmaserame, Levy, Stellar, de Miguel, Fernando J., Perry, Curtis, Guan, Tianxia, Krystal, Gerald, Lockwood, William, Zelterman, Daniel, Homer, Robert, Liu, Zongzhi, Kaech, Susan, Politi, Katerina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617639/
https://www.ncbi.nlm.nih.gov/pubmed/31291990
http://dx.doi.org/10.1186/s40425-019-0643-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6617639/
https://www.ncbi.nlm.nih.gov/pubmed/31291990
http://dx.doi.org/10.1186/s40425-019-0643-8

Ejemplares similares